NYSE - Nasdaq Real Time Price USD

Qiagen N.V. (QGEN)

42.20

-0.55

(-1.29%)

At close: May 1 at 4:00:02 PM EDT

42.99

+0.79

+(1.87%)

Pre-Market: 5:08:53 AM EDT

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 28.57% and 21.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 11 hours ago

ADPT

QGEN
-1.29%
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 19 hours ago

SGMO

QGEN
-1.29%
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth

Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks yesterday

QGEN
-1.29%

ARQT
QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control

VENLO, the Netherlands, April 29, 2025--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow that now includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T), a personalized form of cancer immunotherapy.

Business Wire 2 days ago

QGEN
-1.29%
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 2 days ago

QGEN
-1.29%
QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025

VENLO, Netherlands, April 22, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of product and partnership updates designed to strengthen its portfolio for cancer genomic profiling.

Business Wire 9 days ago

QGEN
-1.29%
Is There An Opportunity With Qiagen N.V.'s (NYSE:QGEN) 33% Undervaluation?

Key Insights The projected fair value for Qiagen is US$60.71 based on 2 Stage Free Cash Flow to Equity Qiagen is...

Simply Wall St. 9 days ago

QGEN
-1.29%
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 15 days ago

QGEN
-1.29%
Qiagen Plans 3 New Sample Preparation Instrument Launches Through 2026

Qiagen (QGEN) said Tuesday it plans to launch three new sample preparation instruments, QIAsymphony

PREMIUM
MT Newswires 16 days ago

QGEN
-1.29%
QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation

VENLO, Netherlands, April 15, 2025--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that plans are advancing to launch three new sample preparation instruments during 2025 and 2026 to expand and strengthen its portfolio for automated sample preparation.

Business Wire 17 days ago

QGEN
-1.29%
Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?

Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 21 days ago

BIIB

QGEN
-1.29%
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

VENLO, The Netherlands, April 08, 2025--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025.

Business Wire 23 days ago

QGEN
-1.29%
QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

VENLO, Netherlands, April 06, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earnings per share (EPS), reflecting strong performances across many growth drivers.

Business Wire 25 days ago

QGEN
-1.29%
Qiagen Full Year 2024 Earnings: EPS Misses Expectations

Qiagen ( NYSE:QGEN ) Full Year 2024 Results Key Financial Results Revenue: US$1.98b (flat on FY 2023). Net income...

Simply Wall St. 29 days ago

QGEN
-1.29%
QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts

VENLO, Netherlands, April 01, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAprep&amp Plasmodium Kit and two companion assays to support malaria research and surveillance efforts.

Business Wire last month

QGEN
-1.29%
Bio-Techne Opens New Customer Experience Centre in Germany

TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.

Zacks last month

TECH
-1.43%

QGEN
-1.29%

BIO-B
QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

VENLO, Netherlands, March 31, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.

Business Wire last month

QGEN
-1.29%
Are Qiagen N.V.'s (NYSE:QGEN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Qiagen (NYSE:QGEN) has had a rough three months with its share price down 14%. It seems that the market might have...

Simply Wall St. last month

QGEN
-1.29%
Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?

QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.

Zacks last month

QGEN
-1.29%
The past three-year earnings decline for Qiagen (NYSE:QGEN) likely explains shareholders long-term losses

For many investors, the main point of stock picking is to generate higher returns than the overall market. But the risk...

Simply Wall St. last month

QGEN
-1.29%

Performance Overview

Return	QGEN	S&P 500 (^GSPC)
YTD	-5.23%	-4.72%
1-Year	-1.42%	+11.67%
3-Year	-4.10%	+35.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Qiagen N.V. (QGEN)

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates

Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth

QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control

Why Qiagen (QGEN) is a Top Value Stock for the Long-Term

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025

Is There An Opportunity With Qiagen N.V.'s (NYSE:QGEN) 33% Undervaluation?

Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term

Qiagen Plans 3 New Sample Preparation Instrument Launches Through 2026

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation

Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

Qiagen Full Year 2024 Earnings: EPS Misses Expectations

QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts

Bio-Techne Opens New Customer Experience Centre in Germany

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

Are Qiagen N.V.'s (NYSE:QGEN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?

The past three-year earnings decline for Qiagen (NYSE:QGEN) likely explains shareholders long-term losses

Performance Overview